Paul Zachary Lamberty: Final Debarment Order
Published Date: 2/6/2026
Notice
Summary
Paul Zachary Lamberty is officially banned for 10 years from importing any drugs into the U.S. because he was convicted of serious crimes involving fake and misleading drugs. He didn’t respond to the FDA’s chance to defend himself, so the ban starts on February 6, 2026. If he wants to end the ban early, he can apply anytime but must be careful about sharing private info.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
10-Year Import Ban for Lamberty
Paul Zachary Lamberty is banned for 10 years from importing or offering for import any drug into the United States. The debarment is effective February 6, 2026 and is based on his May 30, 2025 federal felony convictions for conspiracy and introduction of misbranded drugs with intent to defraud and mislead.
Importing With Lamberty Is Prohibited
Importing or offering for import any drug into the United States by, with the assistance of, or at the direction of Paul Zachary Lamberty is a prohibited act under section 301(cc) of the FD&C Act. This prohibition is effective February 6, 2026.
Termination Application & Confidentiality Rules
Mr. Lamberty may apply at any time to ask for early termination of the debarment under section 306(d)(1) of the FD&C Act. Applications submitted electronically will be posted publicly, so confidential information must be submitted as a written/paper submission following the FDA instructions to protect confidential material.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-02336 — Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of Currently Approved Collection: Title-Campus Program Grantee Needs and Progress Assessment Tool
The Department of Justice’s Office on Violence Against Women is asking for more time to keep using a survey tool that helps campus program grantees track their needs and progress. They want your feedback on how this tool works and how to make it easier to use. If you’re involved in these programs, you can share your thoughts by April 7, 2026—no extra costs, just a chance to improve the process!
Next: 2026-02339 — Codex Alimentarius Commission: Meeting of the Codex Committee on Methods of Analysis and Sampling
The U.S. Codex Office is hosting a public video meeting on February 19, 2026, to share info and gather feedback on food testing and sampling rules before the big Codex meeting in Hungary in March. This affects food producers, labs, and anyone interested in food safety standards. Joining the meeting and submitting comments helps shape U.S. positions, with no costs but important deadlines to keep in mind.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in